Adial Pharmaceuticals, Inc (ADIL) financial statements (2021 and earlier)

Company profile

Business Address 1180 SEMINOLE TRAIL
CHARLOTTESVILLE, VA 22901
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments4,4016,7773,869
Cash and cash equivalents4,4016,7773,869
Prepaid expense233831506
Intangible current assets11 
Other undisclosed current assets50164318
Total current assets:5,1367,6734,693
Noncurrent Assets
Intangible assets, net (including goodwill)6  
Intangible assets, net (excluding goodwill)6  
Other noncurrent assets 67
Other undisclosed noncurrent assets350  
Total noncurrent assets:35667
TOTAL ASSETS:5,4917,6804,699
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:1,505539258
Accounts payable649190 
Accrued liabilities857349 
Other undisclosed accounts payable and accrued liabilities  258
Total current liabilities:1,505539258
Noncurrent Liabilities
Total liabilities:1,505539258
Stockholders' equity
Stockholders' equity attributable to parent3,9867,1414,441
Common stock14107
Additional paid in capital35,49127,75716,470
Accumulated deficit(31,520)(20,627)(12,035)
Total stockholders' equity:3,9867,1414,441
TOTAL LIABILITIES AND EQUITY:5,4917,6804,699

Income statement (P&L) ($ in thousands)

12/31/2020
12/31/2019
12/31/2018
Revenues
(Other Operating Income)
376  
Cost of revenue
(Financing Interest Expense)
  (1,167)
Gross profit:376 (1,167)
Operating expenses(10,928)(8,245)(6,987)
Other undisclosed operating income (loss)(376) 1,167
Operating loss:(10,928)(8,245)(6,987)
Nonoperating income (expense)35(347)(4,644)
Investment income, nonoperating32957
Interest and debt expense  (5)
Loss from continuing operations before equity method investments, income taxes:(10,893)(8,591)(11,636)
Other undisclosed income from continuing operations before income taxes  5
Loss from continuing operations before income taxes:(10,893)(8,591)(11,631)
Income tax expense (benefit)446(14,246) 
Loss before gain (loss) on sale of properties:(10,447)(22,838)(11,631)
Other undisclosed net income (loss)(446)14,246 
Net loss available to common stockholders, diluted:(10,893)(8,591)(11,631)

Comprehensive Income ($ in thousands)

12/31/2020
12/31/2019
12/31/2018
Net loss:(10,893)(8,591)(11,631)
Comprehensive loss, net of tax, attributable to parent:(10,893)(8,591)(11,631)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: